SCHEDULE: FMR LLC Discloses 11.7% Stake in Travere Therapeutics

FMR LLC and Abigail P. Johnson have reported an 11.7% beneficial ownership stake in Travere Therapeutics Inc. as of December 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, beneficially own 10,567,302.78 shares of Travere Therapeutics Inc. common stock.
• This aggregate amount represents 11.7% of the total outstanding common stock of Travere Therapeutics Inc.
• FMR LLC holds sole voting power over 10,224,163.76 shares and sole dispositive power over 10,567,302.78 shares.
• Abigail P. Johnson, as a control person of FMR LLC, is deemed to have sole dispositive power over 10,567,302.78 shares.
• The securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Travere Therapeutics Inc.
• FMR LLC is classified as a parent holding company or control person, and Abigail P. Johnson is classified as an individual.
• Several FMR LLC subsidiaries, including Fidelity Management & Research Company LLC, are identified as entities that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a Schedule 13G is a factual disclosure of ownership and does not contain performance data, the revelation of a significant 11.7% stake by a prominent institutional investor like FMR LLC can be perceived as a strong vote of confidence in the issuer's future prospects and underlying value.

Positives

• The disclosure of a significant 11.7% stake by a major institutional investor like FMR LLC can be interpreted as a vote of confidence in Travere Therapeutics Inc.'s long-term prospects.
• Increased institutional ownership often signals a thorough due diligence process and belief in the company's value proposition.

Industry Context

The disclosure of a significant institutional stake in a biotechnology company like Travere Therapeutics Inc. is a common occurrence in the sector, where long-term investment in promising drug pipelines and therapeutic areas is typical. Such investments by large asset managers like FMR LLC often reflect a strategic position based on the company's clinical development, market potential, or intellectual property.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional stake may lead to increased investor confidence and potentially influence the stock's trading volume and price.
• Company Management: Awareness of a large institutional holder may influence strategic decisions, though the filing explicitly states the stake is not for control purposes.

Key Dates

Keywords

Travere Therapeutics, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Institutional Investment, Common Stock, Biotechnology, Pharmaceuticals